We aimed to provide an updated narrative review with respect to the RET pathogenic variants and their implications at the clinical (dermatology and endocrinology assessments) and molecular level in the diagnosis of MTC/multiple endocrine neoplasia (MEN) type 2, particularly with respect to the presence of cutaneous lichen amyloidosis (CLA). The gene discussed is RET; the disease is multiple endocrine neoplasia.